Inhibition of HIV-1 infection by an intramolecular antisense peptide to T20 in gp160

Microbiology and Immunology

Volumn 44, Issue 3, 2000, Pages 205-212

  Imai, Masaki ^a   Okada, Noriko ^a   Okada, Hidechika ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Antisense peptide; Gp160; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RNA TRANSLATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034027019     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2000.tb02485.x     Document Type: Article

References (42)

1. Allan, J.S., Coligan, J.E., Barin, F., McLane, M.F., Sodroski J.G., Rosen, C.A., Haseltine, W.A., Lee, T.H., and Essex, M. 1985. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228 1091-1094.
2. Baranyi, L., Campbell, W., Ohshima, K., Fujimoto, S. Boros, M., and Okada, H. 1995. The antisense homology box: a new motif within proteins that encodes biologically active peptides. Nat. Med. 1: 894-901.
3. Baranyi, L., Campbell, W., and Okada, H. 1996. Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides J. Immunol. 157: 4591-601.
4. Baranyi, L., Campbell, W., Ohshima, K., Fujimoto, S. Boros, M., Kaszaki, J., and Okada, H. 1998. Antisense homology box-derived peptides represent a new class of enduthelin receptor inhibitors. Peptides 19: 211-223.
5. Blalock, J.E., and Smith, E.M. 1984. Hydropathic anti-complementarity of amino acids based on the genetic eode. Biochem. Biophys. Res. Commun. 121: 203-207.
6. Blalock, J.E. 1990. Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA. Trends Biotechnol.8: 140-144.
7. Blalock, J.E. 1995. Genetic origins of protein shape and interaction rules. Nat. Med. 1: 876-878.
8. Chan, D.C., Fass, D., Berger, J.M., and Kim, P.S. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
9. Chan, D.C., and Kim, P.S. 1998. HIV entry and its inhibition. Cell 93: 681-684.
10. Chan, D.C., Chutkowski, C.T., and Kim, P.S. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 95: 15613-15617.
11. ) Earl. P.L., Moss, B., and Doms, R.W. 1991. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 65: 2047-2055.
12. Eberle, A.N., and Huber, M. 1991. Antisense peptides: tools for receptor isolation? Lack of antisense MSH and ACTH to interact with their sense peptides and to induce receptor-specific antibodies. J. Recept. Res. 11: 13-43.
13. Eckert, D.M., Malashkevich, V.N., Hong. L.H., Carr, P.A., and Kim, P.S. 1999. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
14. Goldstein, A., and Brutlag, D.L. 1989. Is there a relationship between DNA sequences encoding peptide ligands and their receptors? Proc. Natl. Acad. Sci. U.S.A. 86: 42-45.
15. Guillemette, G., Boulay, G., Gagnon, S., Bosse. R., and Escher, E. 1989. The peptide encoded by angiotensin II complementary RNA does not interfere with angiotensin II action. Biochem. J. 261: 309.
16. Gurgo, C., Guo, H.G., Franchini, G., Aldovini, A., Collalti, E., Farrell, K., Wong-Staal, F., Gallo, R.C., and Reitz, M.S., Jr. 1988. Envelope sequences of two new United States HIV-1 isolates. Virology 164: 531-536.
17. Harada, S., Koyanagi, Y., and Yamamoto, N. 1985. Infection of HTLV-III/LAV in HTLV-I-carry ing cells MT-2 and MT-4 and application in a plaque assay. Science 229: 563-566.
18. Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K.I., Shirakawa, S., and Miyoshi, I. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. U.S.A. 78: 6476-6480.
19. Kaiser, E.T., and Kezdy, F.J. 1983. Secondary structures of proteins and peptides in amphiphilic environments. Proc. Natl. Acad. Sci. U.S.A. 80: 1137-1143.
20. Kilby, J.M., Hopkins, S., Venetta, T.M., DiMassimo, B., Cloud, G.A., Lee, J.Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M.R., Nowak, M.A., Shaw, G.M., and Saag, M.S. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4: 1302-1307.
21. Kropelin, M., Susal, C., Daniel, V., and Opelz, G. 1998. Inhibition of HIV-1 rgp120 binding to CD4+ T cells by monoclonal antibodies directed against the gp120C1 or C4 region, Immunol. Lett. 63: 19-25.
22. Lapham, C.K., Ouyang, J., Chandrasekhar, B., Nguyen, N.Y, Dimitrov, D.S., and Golding, H. 1996. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274: 602-605.
23. Li, Y.Y., and Perez, L.G. 1997. The entire SU subunit is required for the incorporation of the HIV-1 envelope glycoprotein complex into virions. Virus Genes 14: 211-223.
24. Markus, G., Tritsch, G.L., and Parthasarathy, R. 1989. A model for hydropathy-based peptide interactions. Arch. Biochem. Biophys. 272: 433-439.
25. Martins, V.R., Graner, E., Garcia-Abreu, J., de Souza, S.J., Mercadante, A.F., Veiga, S.S., Zanata, S.M., Neto. V.M., and Brentani, R.R. 1997. Complementary hydropathy identities a cellular prion protein receptor. Nat. Med. 3: 1376-1382.
26. Misse, D., Cerutti, M., Schmidt, I., Jansen, A., Devauchelle, G., Jansen, F., and Veas, F. 1998. Dissociation of the CD4 and CXCR4 binding properties of human immunodeficiency virus type 1 gp120 by deletion of the first putative alphahelical conserved structure. J. Virol. 72: 7280-7288.
27. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq. E. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20: 309-321.
28. Rasmussen, U.B., and Hesch, R.D. 1987. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem. Biophys. Res. Commun. 149: 930-938.
29. Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., Doran, E.R., Rafalski, J.A., Whitehorn, E.A., and Baumeister, K. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III Nature 313: 277-284.
30. Ruiz-Opazo, N., Akimoto, K., and Herrera, V.L. 1995. Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nat. Med. 1: 1074-1081.
31. Sakaida, H., Hori, T., Yonezawa, A., Sato, A., Isaka, Y., Yoshie, O., Hattori, T., and Uchiyama, T. 1998. T-tropic human immunodeficiency virus type 1 (HIV-1 (-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J. Virol. 72: 9763-9770.
32. Sattentau, Q.J., and Moore, J.P. 1991. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174: 407-415.
33. Sattentau, Q.J., Moore, J.P., Vignaux, F., Traincard, F., and Poignard, P. 1993. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67: 7383-7393.
34. Sodroski, J.G. 1999. HIV-1 entry inhibitors in the side pocket. Cell 99: 243-246.
35. Stern, B., Denisova, G., Buyaner, D., Raviv, D., and Gershoni, J.M. 1997. Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library. FASEB J. 11: 147-153.
36. Takeuchi, H., Baba, M., and Shigeta, S. 1991. An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds. J. Virol. Methods 33: 61-71.
37. Trkola, A., Dragic, T., Arthos, J., Binley, J.M., Olson, W.C., Allaway, G.P., Cheng-Mayer, C., Robinson, J., Maddon, P.J., and Moore, J.P. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384: 184-187.
38. Tropsha, A., Kizer, J.S., and Chaiken, I.M. 1992. Making sense from antisense: a review of experimental data and developing ideas on sense - antisense peptide recognition. J. Mol. Recognit. 5: 43-54.
39. Turner, B.G., and Summers, M.F. 1999. Structural biology of HIV. J. Mol. Biol. 285: 1-32.
40. Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B., and Matthews, T.J. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 91: 9770-9774.
41. Wu, L., Gerard, N.P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A.A., Desjardin, E., Newman, W., Gerard, C., and Sodroski, J. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183.
42. Wyatt, R., Desjardin, E., Olshevsky, U., Nixon, C., Binley, J., Olshevsky, V., and Sodroski, J. 1997. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J. Virol. 71: 9722-9731.